secwatch.observer — SEC 8-K summary
======================================

Issuer:     CapForce Inc. (CFOR)
CIK:        0001293818
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001079973-22-001411
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OpGen Q3 revenue drops to $0.4M from $1.2M; net loss $14.1M; cash down to $10.3M
--------------------------------------------------------------------------------

- Total revenue $0.4M for Q3 2022 vs $1.2M in Q3 2021; net loss $14.1M ($0.30/sh) vs $6.1M loss.
- Cash and equivalents $10.3M as of Sept 30, 2022, down from $36.1M at Dec 31, 2021.
- Elected Yvonne Schlaeppi as independent director; she brings legal, governance, life sciences experience.
- Completed enrollment of >1,800 samples for Unyvero UTI trial; anticipates FDA submission in 2023.
- Full-year 2022 revenue guidance $2.5M to $3M; exploring additional financing and strategic alternatives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1293818/000107997322001411/0001079973-22-001411-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1293818/000107997322001411/opgen_8k-110922.htm
  HTML page:      https://secwatch.observer/filing/0001079973-22-001411

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer